Nachrichten zur MOLECULAR PARTNERS SF 1 Aktie

GNW-News: Molecular Partners gibt Finanzergebnisse für das erste Halbjahr 2026 und wichtige Unternehmensentwicklungen bekannt: DLL3-Radiotherapie-Kandidat MP0712 erreicht in der Phase-1/2a-Studie die nächsthöhere Dosisstufe

^* Auf DLL3 abzielendes Radio-DARPin MP0712 in Phase-1/2a-Studie; Rekrutierung auf Dosisstufe 2 läuft,…

Molecular Partners to Hold Three Poster Presentations at AACR 2026

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN),…

Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript

…

Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

…

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, June 22, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to…

Molecular Partners reports Q1 results

…

Molecular Partners: Sluggish Progress But Worth Monitoring (Rating Downgrade)

…

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., and PARIS, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to…

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53…

Molecular Partners und Orano stärken Partnerschaft

Das Biotechunternehmen Molecular Partners wird künftig noch enger mit dem bisherigen Partner Orano Med zusammenarbeiten.…

Molecular Partners Reports H1 2024 Corporate Highlights and Financials

First Radio-DARPin Therapy (RDT) candidate MP0712 nominated; supporting preclinical package presented at SNMMI; initial clinical data expected in 2025…

Molecular Partners: A Speculative Bet On Innovative DARPin Technology

…

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN),…

Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, June 11, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to…